WO2006067608A1 - Aqueous formulations based on sodium hyaluronate for parenteral use - Google Patents

Aqueous formulations based on sodium hyaluronate for parenteral use Download PDF

Info

Publication number
WO2006067608A1
WO2006067608A1 PCT/IB2005/003918 IB2005003918W WO2006067608A1 WO 2006067608 A1 WO2006067608 A1 WO 2006067608A1 IB 2005003918 W IB2005003918 W IB 2005003918W WO 2006067608 A1 WO2006067608 A1 WO 2006067608A1
Authority
WO
WIPO (PCT)
Prior art keywords
naoh
aqueous formulation
naci
acid
sodium hyaluronate
Prior art date
Application number
PCT/IB2005/003918
Other languages
French (fr)
Inventor
Stefano Carlino
Original Assignee
Laboratoire Medidom S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Medidom S.A. filed Critical Laboratoire Medidom S.A.
Publication of WO2006067608A1 publication Critical patent/WO2006067608A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • the present invention concerns aqueous formulations based on sodium hyaluronate for parenteral use.
  • Sodium hyaluronate is the sodium salt of hyaluronic acid, a mucoid polysaccharide of biological origin, which is known as one of the major components of synovial fluid and which is also present in various connective tissues such as skin and cartilage.
  • hyaluronic acid is a member of glycosaminoglycans and it is constituted by alternating and repeating units of D-glucuronic acid and N-acetyl- D-glucosamine, to form a linear chain having a molecular weight up to 13 x 10 6 Daltons.
  • aqueous formulations based on sodium hyaluronate for intra-articular use are usually composed of sodium hyaluronate as active ingredient, and further of some salts as sodium chloride for obtaining the physiological osmolarity of 270 - 330 mOsm/l and sodium phosphate as a buffer for maintaining the pH in the range of 6.8 to 7.6, preferably at a physiological pH of 7.4.
  • WO-A-89 01777 discloses a lubricant composition for intra-articular use, which is useful to reduce the coefficient of kinetic friction imparted to the boundary surface of a joint upon articulation, said lubricant composition comprising at least one phospholipid in a relatively high concentration and hyaluronic acid or a water soluble salt thereof in phosphate-buffered saline solution.
  • HA with a high molecular weight in particular with an average molecular weight above 500'0OO Daltons, is preferred in many applications in view of the superior visco-elastic properties, residence time and tolerance in the body compared to lower molecular weight HA.
  • Known aqueous HA formulations however suffer from degradation by hyaluronidase enzymes, and as a consequence a deterioration of the sought after properties of the HA.
  • An object of this invention is to provide an aqueous high molecular weight HA formulation for parenteral uses, such as for intra-articular use or for tissue augmentation, that is stable over a long period of time, in particular that is resistant to degradation by enzymes.
  • hyaluronate polymer by hyaluronidase In order to overcome the problem of degradability of hyaluronate polymer by hyaluronidase, the inventors of the present invention have made extensive studies to provide an aqueous formulation based on sodium hyaluronate for parenteral use, such as for intra-articular use or for soft tissue augmentation, which has an improved resistance to degradation of hyaluronate polymer by hyaluronidase and consequently which has, inter alia, an increased residence time at the site of application.
  • the inventors have found that the presence of sodium chloride in known aqueous HA formulations, which is primarily intended to provide a physiological osmolarity for parenteral use, surprisingly has an adverse influence on the resistance to hyaluronidase degradation of the HA polymer.
  • the inventors have further found that in the absence of sodium chloride, a wide range of amphoters - which includes fatty acids, fatty acid esters, phospholipids, sphingolipids, and gangliosides - inhibit hyaluronidase enzyme activity very effectively.
  • the object of the invention has been achieved as a result of the unexpected findings that sodium chloride, which is usually contained in known aqueous sodium hyaluronate formulations for parenteral use, may be advantageously replaced by a non saline physiologically acceptable osmogen, to provide an aqueous formulation having physiological osmolarity.
  • a suitable buffer can be added, unless the osmogen itself can act as a buffer in the physiological range.
  • the hyaluronate polymer In combination with an amphoter, acting as a hyaluronidase activity inhibitor, the hyaluronate polymer has a resistance to hyaluronidase that is, in vitro, more than 30 times greater than hyaluronate polymer contained in the known formulations containing sodium chloride.
  • the non saline osmogen may advantageously be an amino acid selected from a group comprising histidine, valine, proline and cysteine.
  • the osmogen may also be: a polyalchohol phosphoric ester such as glycerophosphate; a polyol such as mannitol, sorbitol, glycerol or xylitol; a monosaccharide such as glucose, galactose, xylose, fructose, galactosamine, glucosamine, neuraminic acid, and glucuronic acid; or a disaccharide such as sucrose, maltose and lactose.
  • a polyalchohol phosphoric ester such as glycerophosphate
  • a polyol such as mannitol, sorbitol, glycerol or xylitol
  • a monosaccharide such as glucose, galactose, x
  • an advantage of the use of an amino acid selected from a group comprising histidine, valine, proline and cysteine, and particularly histidine is that the amino acid itself acts as a buffer in the physiological pH and gives the physiological osmolarity when added in an appropriate amount, thus providing an aqueous formulation for parenteral use comprising sodium hyaluronate having an improved resistance to degradation by hyaluronidase due to the absence of sodium chloride and phosphate buffer and therefore an increased residence time at the site of application.
  • an aqueous formulation for parenteral use such as intra-articular use or soft tissue augmentation, comprising sodium hyaluronate having a very high resistance to degradation by hyaluronidase, and therefore an optimal residence time at the site of application, may be obtained by adding a small amount of an amphoter (amphoteric compound) such as a phospholipid to a non-saline aqueous formulation comprising sodium hyaluronate,or other salt of hyaluronic acid, and a non saline osmogen such as histidine.
  • amphoter amphoteric compound
  • Fig. 1 represents a graph showing elastic module kinetics during incubation at 37°C with hyaluronidase in two different formulations, namely a formulation according to the present invention and a comparative formulation.
  • the aqueous formulation for parenteral use of the present invention comprises between 0.01 to 3 % w/v sodium hyaluronate having a molecular weight from 500,000 to 5,000,000 Daltons.
  • the molecular weight of sodium hyaluronate used in the present invention may be determined by known techniques such as gel permeation chromatography or by measuring intrinsic viscosity.
  • Said aqueous formulation for parenteral use of the present invention is characterized in that it further comprises non saline osmogen in an effective amount to impart to the aqueous formulation a physiological osmolarity of from 270 - 330 mOsm/l and a physiological pH from 6.8 - 7.6, preferably 7.4., or a non saline osmogen plus a suitable buffer capable of maintaining the pH in the physiological range.
  • Sodium hyaluronate of molecular weights lower than 500,000 D are not appropriate for use in the present invention because of the insufficient visco- elastic properties, the lower residence time and reduced tolerance and increased irritation in the body compared to higher molecular weight HA.
  • a formulation having a content of sodium hyaluronate greater than 3 % wt/v is not appropriate for parenteral use since it forms a very high viscosity gel that is difficult to administer by injection, for example.
  • the sodium hyaluronate is used in an amount of 0.2 to 2 % wt/v, based on the total aqueous formulation.
  • Said aqueous formulation for intra-articular use of the present invention comprises both a non saline osmogen in an effective concentration to impart to the aqueous formulation a physiological osmolarity of from 270-330 mOsm/l and a physiological pH of from 6.8-7.6, or a non saline osmogen plus a suitable buffer.
  • the non saline osmogen is preferably an amino acid selected from a group comprising histidine, valine, proline and cysteine, such substances being able to buffer at the physiological pH.
  • a suitable buffer such as an amino acid selected from a group comprising histidine, valine, proline, asparagine and cysteine
  • an osmogen such as a polyalchohol phosphoric ester such as glycerophosphate; a polyol such as mannitol, sorbitol, glycerol or xylitol; a monosaccharide such as glucose, galactose, xylose, fructose, galactosamine, glucosamine, neuraminic acid, and glucuronic acid; or a disaccharide such as sucrose, maltose and lactose.
  • an osmogen such as a polyalchohol phosphoric ester such as glycerophosphate
  • a polyol such as mannitol, sorbitol, glycerol or xylitol
  • a monosaccharide such as glucose, galactose,
  • sodium hyaluronate also contributes to the osmolarity of the formulation, said contribution depending on the concentration and molecular weight of sodium hyaluronate present in the formulation.
  • the effective concentration range of osmogen to impart to the aqueous formulation a physiological osmolarity of from 270-330 mOsm/l will depend on the concentration and molecular weight of the sodium hyaluronate present in the formulation.
  • a solution of 36, 40 and 44 g/l of histidine gives an osmolarity of 220, 246 and 268 mOsm/l, respectively.
  • sodium hyaluronate having a molecular weight of 1'80OOOO D is added in an amount of 1 % w/v to the solution, the osmolarity becomes 271 , 298 and 310 m ⁇ sm/l, respectively.
  • sodium hyaluronate having an average molecular weight of 1'800'000 D in an amount of 1 % w/v contributes to about 50 m ⁇ sm/l.
  • An advantage of using an amino acid, and in particular histidine, as an osmogen, is that it results in a physiological pH at all concentrations of histidine if the physiological osmolarity is achieved in the formulation containing sodium hyaluronate. An additional buffer is thus not needed.
  • Presence of histidine in an effective amount to impart a physiological osmolarity in the aqueous formulation containing sodium hyaluronate allows to improve the resistance of hyaluronate to hyaluronidase by 2 - 3 times compared with classical formulations containing sodium chloride and phosphate buffer instead of histidine.
  • the aqueous formulation of the present invention may be prepared according to conventional techniques by adding histidine in water previously heated at a temperature up to 40 0 C and stirring until complete dissolution of histidine into water, and then by further adding thereto sodium hyaluronate and stirring until complete dissolution of sodium hyaluronate into the histidine solution.
  • the aqueous formulation further contains up to 1 % w/v phospholipid based on the total aqueous formulation.
  • Phospholipids which can be used in the present invention may be any naturally or artificially synthesized phospholipids and are preferably selected from phosphatide acid, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, sphingomyelin and derivatives thereof.
  • Presence of a small amount of phospholipid in the aqueous formulation of the present invention containing sodium hyaluronate and histidine is advantageous in the sense that it allows to impart to hyaluronate a drastically improved resistance to degradation by hyaluronidase.
  • the aqueous formulation of the present invention further containing phospholipid may be prepared according to conventional techniques by adding a suspension of phospholipid, previously prepared by adding phospholipid to water heated at a temperature up to 50 0 C, to the aqueous formulation according to the present invention containing histidine and sodium hyaluronate and stirring until the formulation be homogeneous.
  • buffers including: common buffers such as citric acid, cacodylic acid Sodium salt-HCI, and imidazole-HCI; peptides such as carnosine, amino acid such as histidine, proline, valine or cysteine; and Zwitterionic buffers such as Glycyl-glycine-piperazine ⁇ HCI-NaOH, MES-NaOH-NaCI, TRIS-malic acid-NaOH, ADA-NaOH-NaCI, ACES-NaOH-NaCI, BES-NaOH-NaCI, MOPS- NaOH-NaCI, TES-NaOH-NaCI, MOPS-KOH, HEPES-NaOH-NaCI, TRIS-HCI, HEPPSO-NaOH, and BICINE-NaOH-NaCI.
  • common buffers such as citric acid, cacodylic acid Sodium salt-HCI, and imidazole-HCI
  • peptides such as car
  • the aqueous formulation for parenteral use of the present invention is particularly useful for intra-articular administration or soft tissue augmentation and has the advantage of showing an increased residence time at the site of application for the reason that hyaluronate polymer contained in the formulation has an improved resistance to degradation by hyaluronidase.
  • Example 1 Preparation of a formulation according to a preferred embodiment of the present invention containing 1 % w/v of sodium hvaluronate, in which the formulation contains a single substance that acts as an osmogen and as a buffer.
  • the formulation is prepared as follows:
  • Solution B is poured into Solution A under stirring conditions, to prepare 2 liter of a formulation according to an embodiment of the present invention.
  • Example 2 Preparation of a formulation according to a preferred embodiment of the present invention containing 2 % w/v of sodium hvaluronate. in which the the formulation contains a substance that acts as an osmogen and another substance which acts as a buffer.
  • the formulation is prepared as follows:
  • Solution A and solution B are mixed together and the pH is adjusted at 7.4 with sulfuric acid 10% in water for injection.
  • FIG. 1 the elastic module kinetics of the formulation according to the above example (IF), and a conventional HA saline aqueous formulation (CF) is measured during incubation with hyaluronidase at 37 degrees Celsius.
  • the known formulation is a formulation at 2% concentration of sodium hyaluronate in a saline aqueous solution commercialised by the firm TRB Chemedica SA (Switzerland) under the tradename "VISIOL".

Abstract

An aqueous formulation for parenteral use, comprises sodium hyaluronate having a molecular weight from 500,000 to 5,000,000 D in an amount from 0.01 to 3 % w/v, based on the aqueous formulation, a non saline physiologically acceptable osmogen in an effective amount to impart to the aqueous formulation a physiological osmolarity of from 270-330 mOsm/l, and an amphoter acting as an inhibitor of hyaluronidase activity.

Description

AQUEOUS FORMULATIONS BASED ON SODIUM HYALURONATE FOR
PARENTERAL USE
The present invention concerns aqueous formulations based on sodium hyaluronate for parenteral use.
Sodium hyaluronate is the sodium salt of hyaluronic acid, a mucoid polysaccharide of biological origin, which is known as one of the major components of synovial fluid and which is also present in various connective tissues such as skin and cartilage.
Chemically, hyaluronic acid is a member of glycosaminoglycans and it is constituted by alternating and repeating units of D-glucuronic acid and N-acetyl- D-glucosamine, to form a linear chain having a molecular weight up to 13 x 106 Daltons.
Formulations containing sodium hyaluronate, inter alia for intra-articular use, are widely described in the literature.
Known aqueous formulations based on sodium hyaluronate for intra-articular use are usually composed of sodium hyaluronate as active ingredient, and further of some salts as sodium chloride for obtaining the physiological osmolarity of 270 - 330 mOsm/l and sodium phosphate as a buffer for maintaining the pH in the range of 6.8 to 7.6, preferably at a physiological pH of 7.4.
WO-A-89 01777 discloses a lubricant composition for intra-articular use, which is useful to reduce the coefficient of kinetic friction imparted to the boundary surface of a joint upon articulation, said lubricant composition comprising at least one phospholipid in a relatively high concentration and hyaluronic acid or a water soluble salt thereof in phosphate-buffered saline solution.
HA with a high molecular weight, in particular with an average molecular weight above 500'0OO Daltons, is preferred in many applications in view of the superior visco-elastic properties, residence time and tolerance in the body compared to lower molecular weight HA. Known aqueous HA formulations however suffer from degradation by hyaluronidase enzymes, and as a consequence a deterioration of the sought after properties of the HA. An object of this invention is to provide an aqueous high molecular weight HA formulation for parenteral uses, such as for intra-articular use or for tissue augmentation, that is stable over a long period of time, in particular that is resistant to degradation by enzymes.
In order to overcome the problem of degradability of hyaluronate polymer by hyaluronidase, the inventors of the present invention have made extensive studies to provide an aqueous formulation based on sodium hyaluronate for parenteral use, such as for intra-articular use or for soft tissue augmentation, which has an improved resistance to degradation of hyaluronate polymer by hyaluronidase and consequently which has, inter alia, an increased residence time at the site of application.
The inventors have found that the presence of sodium chloride in known aqueous HA formulations, which is primarily intended to provide a physiological osmolarity for parenteral use, surprisingly has an adverse influence on the resistance to hyaluronidase degradation of the HA polymer.
Without wishing to be bound by theory, it is believed that the reduced resistance of HA in aqueous saline solution is probably due to a modification in the conformation of the hyaluronate network in aqueous solution when sodium chloride is present, which better exposes the polymer chains to an attack by the enzymes.
The inventors have further found that in the absence of sodium chloride, a wide range of amphoters - which includes fatty acids, fatty acid esters, phospholipids, sphingolipids, and gangliosides - inhibit hyaluronidase enzyme activity very effectively.
Thus, according to the present invention, the object of the invention has been achieved as a result of the unexpected findings that sodium chloride, which is usually contained in known aqueous sodium hyaluronate formulations for parenteral use, may be advantageously replaced by a non saline physiologically acceptable osmogen, to provide an aqueous formulation having physiological osmolarity. In order to maintain the physiological pH, a suitable buffer can be added, unless the osmogen itself can act as a buffer in the physiological range. In combination with an amphoter, acting as a hyaluronidase activity inhibitor, the hyaluronate polymer has a resistance to hyaluronidase that is, in vitro, more than 30 times greater than hyaluronate polymer contained in the known formulations containing sodium chloride.
The non saline osmogen may advantageously be an amino acid selected from a group comprising histidine, valine, proline and cysteine. The osmogen may also be: a polyalchohol phosphoric ester such as glycerophosphate; a polyol such as mannitol, sorbitol, glycerol or xylitol; a monosaccharide such as glucose, galactose, xylose, fructose, galactosamine, glucosamine, neuraminic acid, and glucuronic acid; or a disaccharide such as sucrose, maltose and lactose.
An advantage of the use of an amino acid selected from a group comprising histidine, valine, proline and cysteine, and particularly histidine, is that the amino acid itself acts as a buffer in the physiological pH and gives the physiological osmolarity when added in an appropriate amount, thus providing an aqueous formulation for parenteral use comprising sodium hyaluronate having an improved resistance to degradation by hyaluronidase due to the absence of sodium chloride and phosphate buffer and therefore an increased residence time at the site of application.
Thus, the present inventors have surprisingly found that an aqueous formulation for parenteral use, such as intra-articular use or soft tissue augmentation, comprising sodium hyaluronate having a very high resistance to degradation by hyaluronidase, and therefore an optimal residence time at the site of application, may be obtained by adding a small amount of an amphoter (amphoteric compound) such as a phospholipid to a non-saline aqueous formulation comprising sodium hyaluronate,or other salt of hyaluronic acid, and a non saline osmogen such as histidine. Other objects and advantageous aspects of the present invention will be apparent from the claims and following detailed description and accompanying figure, in which:
Fig. 1 represents a graph showing elastic module kinetics during incubation at 37°C with hyaluronidase in two different formulations, namely a formulation according to the present invention and a comparative formulation.
The aqueous formulation for parenteral use of the present invention comprises between 0.01 to 3 % w/v sodium hyaluronate having a molecular weight from 500,000 to 5,000,000 Daltons. The molecular weight of sodium hyaluronate used in the present invention, which is commercially available, may be determined by known techniques such as gel permeation chromatography or by measuring intrinsic viscosity.
Said aqueous formulation for parenteral use of the present invention is characterized in that it further comprises non saline osmogen in an effective amount to impart to the aqueous formulation a physiological osmolarity of from 270 - 330 mOsm/l and a physiological pH from 6.8 - 7.6, preferably 7.4., or a non saline osmogen plus a suitable buffer capable of maintaining the pH in the physiological range.
Sodium hyaluronate of molecular weights lower than 500,000 D are not appropriate for use in the present invention because of the insufficient visco- elastic properties, the lower residence time and reduced tolerance and increased irritation in the body compared to higher molecular weight HA.
A formulation having a content of sodium hyaluronate greater than 3 % wt/v is not appropriate for parenteral use since it forms a very high viscosity gel that is difficult to administer by injection, for example.
Preferably, the sodium hyaluronate is used in an amount of 0.2 to 2 % wt/v, based on the total aqueous formulation.
Said aqueous formulation for intra-articular use of the present invention comprises both a non saline osmogen in an effective concentration to impart to the aqueous formulation a physiological osmolarity of from 270-330 mOsm/l and a physiological pH of from 6.8-7.6, or a non saline osmogen plus a suitable buffer. In a first embodiment, the non saline osmogen is preferably an amino acid selected from a group comprising histidine, valine, proline and cysteine, such substances being able to buffer at the physiological pH. In a second embodiment, a suitable buffer such as an amino acid selected from a group comprising histidine, valine, proline, asparagine and cysteine, is associated with an osmogen such as a polyalchohol phosphoric ester such as glycerophosphate; a polyol such as mannitol, sorbitol, glycerol or xylitol; a monosaccharide such as glucose, galactose, xylose, fructose, galactosamine, glucosamine, neuraminic acid, and glucuronic acid; or a disaccharide such as sucrose, maltose and lactose.
It is known that sodium hyaluronate also contributes to the osmolarity of the formulation, said contribution depending on the concentration and molecular weight of sodium hyaluronate present in the formulation.
Therefore, the effective concentration range of osmogen to impart to the aqueous formulation a physiological osmolarity of from 270-330 mOsm/l will depend on the concentration and molecular weight of the sodium hyaluronate present in the formulation.
By way of example, a solution of 36, 40 and 44 g/l of histidine gives an osmolarity of 220, 246 and 268 mOsm/l, respectively. When sodium hyaluronate having a molecular weight of 1'80OOOO D is added in an amount of 1 % w/v to the solution, the osmolarity becomes 271 , 298 and 310 mθsm/l, respectively.
This means that sodium hyaluronate having an average molecular weight of 1'800'000 D in an amount of 1 % w/v contributes to about 50 mθsm/l.
The higher the concentration of sodium hyaluronate, the lower is the amount of osmogen (for example histidine) needed to impart to the aqueous formulation a physiological osmolarity of from 270-330 mθsm/l, and the higher the molecular weight of sodium hyaluronate, the lower the amount of histidine is needed to impart to the aqueous formulation a physiological osmolarity of from 270-330 mOsm/l. An advantage of using an amino acid, and in particular histidine, as an osmogen, is that it results in a physiological pH at all concentrations of histidine if the physiological osmolarity is achieved in the formulation containing sodium hyaluronate. An additional buffer is thus not needed.
Presence of histidine in an effective amount to impart a physiological osmolarity in the aqueous formulation containing sodium hyaluronate allows to improve the resistance of hyaluronate to hyaluronidase by 2 - 3 times compared with classical formulations containing sodium chloride and phosphate buffer instead of histidine.
In an embodiment of the invention, the aqueous formulation of the present invention may be prepared according to conventional techniques by adding histidine in water previously heated at a temperature up to 400C and stirring until complete dissolution of histidine into water, and then by further adding thereto sodium hyaluronate and stirring until complete dissolution of sodium hyaluronate into the histidine solution.
In a preferred embodiment of the present invention, the aqueous formulation further contains up to 1 % w/v phospholipid based on the total aqueous formulation.
Phospholipids which can be used in the present invention may be any naturally or artificially synthesized phospholipids and are preferably selected from phosphatide acid, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, sphingomyelin and derivatives thereof.
Presence of a small amount of phospholipid in the aqueous formulation of the present invention containing sodium hyaluronate and histidine is advantageous in the sense that it allows to impart to hyaluronate a drastically improved resistance to degradation by hyaluronidase.
The aqueous formulation of the present invention further containing phospholipid may be prepared according to conventional techniques by adding a suspension of phospholipid, previously prepared by adding phospholipid to water heated at a temperature up to 500C, to the aqueous formulation according to the present invention containing histidine and sodium hyaluronate and stirring until the formulation be homogeneous.
In case the non-saline osmogen added to the formulation does not act as a buffer, various physiologically acceptable buffers may be added to the formulation, these buffers including: common buffers such as citric acid, cacodylic acid Sodium salt-HCI, and imidazole-HCI; peptides such as carnosine, amino acid such as histidine, proline, valine or cysteine; and Zwitterionic buffers such as Glycyl-glycine-piperazine^HCI-NaOH, MES-NaOH-NaCI, TRIS-malic acid-NaOH, ADA-NaOH-NaCI, ACES-NaOH-NaCI, BES-NaOH-NaCI, MOPS- NaOH-NaCI, TES-NaOH-NaCI, MOPS-KOH, HEPES-NaOH-NaCI, TRIS-HCI, HEPPSO-NaOH, and BICINE-NaOH-NaCI.
The aqueous formulation for parenteral use of the present invention is particularly useful for intra-articular administration or soft tissue augmentation and has the advantage of showing an increased residence time at the site of application for the reason that hyaluronate polymer contained in the formulation has an improved resistance to degradation by hyaluronidase.
EXAMPLES
Example 1 : Preparation of a formulation according to a preferred embodiment of the present invention containing 1 % w/v of sodium hvaluronate, in which the formulation contains a single substance that acts as an osmogen and as a buffer.
1 liter of an aqueous solution of sodium hyaluronate with 1 % concentration are prepared using the following substances:
• L-histidine provided by FLUKA assay 99.5%.
• Sodium hyaluronate provided by H.T.L s.a.r.l. • 1 ,2-Dipalmitoyl-sn-glycero-3-phosphate monosodium salt provided by FLUKA assay 98%
The formulation is prepared as follows:
1. 49 g of histidine are added to 800 ml of water for injection preheated at 400C under stirring conditions
2. After dissolution of histidine is complete, 10 g of sodium hyaluronate are added to the histidine solution and stirred until complete dissolution of sodium hyaluronate is achieved (Solution A).
3. In parallel, a suspension of 1 g of 1 ,2-Dipalmitoyl-sn-glycero-3-phosphate monosodium salt in 200 ml of warm water for injection (40-500C) was prepared (Solution B).
4. Solution B is poured into Solution A under stirring conditions, to prepare 2 liter of a formulation according to an embodiment of the present invention.
Example 2: Preparation of a formulation according to a preferred embodiment of the present invention containing 2 % w/v of sodium hvaluronate. in which the the formulation contains a substance that acts as an osmogen and another substance which acts as a buffer.
1 liter of an aqueous solution of sodium hyaluronate with 2% concentration are prepared using the following substances:
• DL-α-Glycerol phosphate Disodium salt provided by FLUKA assay 90%.
• L-histidine provided by FLUKA assay 99.5%.
• Sodium hyaluronate provided by H.T.L s.a.r.l.
• 1 ,2-Dipalmitoyl-sn-glycero-3-phosphate monosodium salt provided by FLUKA assay 98%
The formulation is prepared as follows:
1. 28g of Glycerol phosphate and 5g of L-histidine are dissolved in 800 ml of water for injection (Solution A). 2. 1 g of 1 ,2-DipalmitoyI-sn-glycero-3-phosphate monosodium salt are dissolved in 200 ml of water for injection at a temperature of 60°C (Solution B).
3. Solution A and solution B are mixed together and the pH is adjusted at 7.4 with sulfuric acid 10% in water for injection.
4. Finally, 2Og of sodium hyaluronate are added to the solution, and stirred, to prepare 2 liter of a formulation according to an embodiment of the present invention.
A solution with an osmolarity of 300 [mθsm/lt] and a pH of 7.4 is obtained. The resistance to hyaluronidase degradation of the formulation obtained is significantly increased as illustrated in Figure 1. In Figure 1 , the elastic module kinetics of the formulation according to the above example (IF), and a conventional HA saline aqueous formulation (CF) is measured during incubation with hyaluronidase at 37 degrees Celsius. The known formulation is a formulation at 2% concentration of sodium hyaluronate in a saline aqueous solution commercialised by the firm TRB Chemedica SA (Switzerland) under the tradename "VISIOL".

Claims

1. An aqueous formulation for parenteral use, comprising sodium hyaluronate having a molecular weight from 500,000 to 5,000,000 D in an amount from 0.01 to 3 % w/v, based on the aqueous formulation, characterized in that it further comprises a non saline physiologically acceptable osmogen in an effective amount to impart to the aqueous formulation a physiological osmolarity of from 270-330 mOsm/l, and an amphoter acting as an inhibitor of hyaluronidase activity.
2. An aqueous formulation according to claim 1 further comprising a physiologically acceptable buffer in an effective amount to impart to the aqueous formulation a physiological pH from 6.8-7.6.
3. The formulation according to claim 2 wherein the physiologically acceptable buffer is selected from the groups comprising: common buffers including citric acid, cacodylic acid Sodium salt-HCI, and imidazole-HCI; peptides including camosine; amino acid such as histidine, proline, valine or cysteine and Zwitterionic buffers inluding Glycyl-gIycine-piperazine-2HCI-NaOH, MES-NaOH- NaCI, TRIS-malic acid-NaOH, ADA-NaOH-NaCl, ACES-NaOH-NaCI, BES- NaOH-NaCI, MOPS-NaOH-NaCI, TES-NaOH-NaCI, MOPS-KOH, HEPES- NaOH-NaCI, TRIS-HCI, HEPPSO-NaOH, and BICINE-NaOH-NaCI.
4. An aqueous formulation according to claim 1 , 2 or 3, wherein the non saline osmogen is an amino acid selected from the group comprising histidine, valine, proline and cysteine.
5. An aqueous formulation according to any one of the preceding claims wherein the non saline osmogen is selected from the groups comprising: a polyalchohol phosphoric ester such as glycerophosphate; a polyol such as mannitol, sorbitol, glycerol or xylitol; a monosaccharide such as glucose, galactose, xylose, fructose, galactosamine, glucosamine, neuraminic acid, and glucuronic acid; and a disaccharide such as sucrose, maltose and lactose.
6. The formulation according to any one of the preceding claims wherein said amphoter is selected from a group of compounds comprising unsaturated fatty acids, fatty acid esters, phospholipids, sphingolipids, and gangliosides.
7. The formulation according to claim 6 wherein the amphoter is a phospholipid selected from a group comprising phosphatidic acid, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, sphingomyelin and derivatives thereof.
8. The formulation according to claim 7 wherein there is less than 1 % w/v of phospholipid, based on the aqueous formulation.
PCT/IB2005/003918 2004-12-22 2005-12-14 Aqueous formulations based on sodium hyaluronate for parenteral use WO2006067608A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04405792.5 2004-12-22
EP04405792 2004-12-22

Publications (1)

Publication Number Publication Date
WO2006067608A1 true WO2006067608A1 (en) 2006-06-29

Family

ID=36023539

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/003918 WO2006067608A1 (en) 2004-12-22 2005-12-14 Aqueous formulations based on sodium hyaluronate for parenteral use

Country Status (1)

Country Link
WO (1) WO2006067608A1 (en)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918276A1 (en) * 2007-07-02 2009-01-09 Anteis Sa Use of polysaccharide gel from natural origin comprising aqueous composition of polysaccharides and biocompatible alcohols for the preparation of injectable formulation to treat articular degeneration and osteoarthritis
FR2938187A1 (en) * 2008-11-07 2010-05-14 Anteis Sa INJECTABLE COMPOSITION BASED ON HYALURONIC ACID OR ONE OF ITS HEAT-STERILIZED SALTS, POLYOLS AND LIDOCAINE
ITMI20092256A1 (en) * 2009-12-21 2011-06-22 Solartium Entpr Ltd USE OF A COMBINATION FOR THE TREATMENT OF OSTEOARTROSI
WO2011110894A2 (en) 2010-03-12 2011-09-15 Allergan Industrie Sas Fluid composition for improving skin conditions
ITBS20100197A1 (en) * 2010-12-06 2012-06-07 Paoli Ambrosi Gianfranco De NEW COMPOUND OF CARNOSINE
RU2454219C2 (en) * 2007-07-02 2012-06-27 Антэ С.А. Application of natural polysaccharide (natural polysaccharides) gel for preparing composition applicable for injection of composition for treating degenerative joint disease
WO2012143876A1 (en) * 2011-04-19 2012-10-26 Anteis S.A. A sterile and injectable aqueous formulation for administration in the intra-articular space of an intra-articular joint
WO2013076162A1 (en) * 2011-11-21 2013-05-30 Université Libre de Bruxelles Formulations useful in the treatment of osteoarticular diseases
WO2013076160A1 (en) * 2011-11-21 2013-05-30 Université Libre de Bruxelles Sustained release formulations useful in the treatment of diseases
US8691279B2 (en) 2010-03-22 2014-04-08 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US8853184B2 (en) 2007-11-30 2014-10-07 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
WO2015006460A1 (en) 2013-07-10 2015-01-15 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
US8946192B2 (en) 2010-01-13 2015-02-03 Allergan, Inc. Heat stable hyaluronic acid compositions for dermatological use
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US9062130B2 (en) 2003-04-10 2015-06-23 Allergan Industrie Sas Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained
US9089519B2 (en) 2008-08-04 2015-07-28 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US9149422B2 (en) 2011-06-03 2015-10-06 Allergan, Inc. Dermal filler compositions including antioxidants
US9228027B2 (en) 2008-09-02 2016-01-05 Allergan Holdings France S.A.S. Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US9265761B2 (en) 2007-11-16 2016-02-23 Allergan, Inc. Compositions and methods for treating purpura
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9795711B2 (en) 2011-09-06 2017-10-24 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US10004824B2 (en) 2015-05-11 2018-06-26 Laboratoires Vivacy Compositions comprising at least one polyol and at least one anesthetic
US10028976B2 (en) * 2007-07-02 2018-07-24 Aptissen Sa Injectable formulation of natural polysaccharide and polyol for treatment of osteoarthritis
US10722444B2 (en) 2014-09-30 2020-07-28 Allergan Industrie, Sas Stable hydrogel compositions including additives
US11083684B2 (en) 2011-06-03 2021-08-10 Allergan Industrie, Sas Dermal filler compositions
US11260015B2 (en) 2015-02-09 2022-03-01 Allergan Industrie, Sas Compositions and methods for improving skin appearance
CN114317497A (en) * 2021-12-14 2022-04-12 华熙生物科技股份有限公司 Hyaluronidase liquid preparation for detection and application thereof
US11844878B2 (en) 2011-09-06 2023-12-19 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138572A2 (en) * 1983-10-11 1985-04-24 FIDIA S.p.A. Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same
WO1989001777A1 (en) * 1987-08-25 1989-03-09 Macnaught Pty. Limited Lubricant composition for rheumatism
AU2320888A (en) * 1987-08-25 1989-03-31 Macnaught Pty Limited Hyaluronic acid lubricating compounds
US4957744A (en) * 1986-10-13 1990-09-18 Fidia, S.P.A. Cross-linked esters of hyaluronic acid
EP0499164A1 (en) * 1991-02-12 1992-08-19 C.R. Bard, Inc. Injectable compositions to replace lubricating body fluids
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
US5679655A (en) * 1993-08-04 1997-10-21 Patent Biopharmaceutics, Inc. Method of treating lesions resulting from genital herpes with hyaluronic acid-urea pharmaceutical compositions
US20010041671A1 (en) * 2000-04-07 2001-11-15 Napoli Guido Di Ophthalmic formulations

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138572A2 (en) * 1983-10-11 1985-04-24 FIDIA S.p.A. Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same
US4957744A (en) * 1986-10-13 1990-09-18 Fidia, S.P.A. Cross-linked esters of hyaluronic acid
WO1989001777A1 (en) * 1987-08-25 1989-03-09 Macnaught Pty. Limited Lubricant composition for rheumatism
AU2320888A (en) * 1987-08-25 1989-03-31 Macnaught Pty Limited Hyaluronic acid lubricating compounds
EP0499164A1 (en) * 1991-02-12 1992-08-19 C.R. Bard, Inc. Injectable compositions to replace lubricating body fluids
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
US5679655A (en) * 1993-08-04 1997-10-21 Patent Biopharmaceutics, Inc. Method of treating lesions resulting from genital herpes with hyaluronic acid-urea pharmaceutical compositions
US20010041671A1 (en) * 2000-04-07 2001-11-15 Napoli Guido Di Ophthalmic formulations

Cited By (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11045490B2 (en) 2003-04-10 2021-06-29 Allergan Industrie, Sas Injectable monophase hydrogels
US9062130B2 (en) 2003-04-10 2015-06-23 Allergan Industrie Sas Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained
US10080767B2 (en) 2003-04-10 2018-09-25 Allergan Industrie Sas Injectable monophase hydrogels
US10653716B2 (en) 2003-04-10 2020-05-19 Allergan Industrie, Sas Injectable monophase hydrogels
EP2173324B1 (en) 2007-07-02 2019-04-10 Aptissen SA Hyaluronic acid injectable gel for treating joint degeneration
JP2010531863A (en) * 2007-07-02 2010-09-30 アンタイス エス．エイ． Use of natural polysaccharide gels for the manufacture of injectable formulations for the treatment of joint degeneration
EP3498262B1 (en) 2007-07-02 2021-09-01 Aptissen SA Hyaluronic acid injectable gel
EP3498262A1 (en) * 2007-07-02 2019-06-19 Aptissen SA Use of a gel of natural polysaccharide(s) for the preparation of an injectable formulation for treating joint degeneration
EP2173324A2 (en) 2007-07-02 2010-04-14 Anteis SA Hyaluronic acid injectable gel for treating joint degeneration
RU2454219C2 (en) * 2007-07-02 2012-06-27 Антэ С.А. Application of natural polysaccharide (natural polysaccharides) gel for preparing composition applicable for injection of composition for treating degenerative joint disease
US10028976B2 (en) * 2007-07-02 2018-07-24 Aptissen Sa Injectable formulation of natural polysaccharide and polyol for treatment of osteoarthritis
FR2918276A1 (en) * 2007-07-02 2009-01-09 Anteis Sa Use of polysaccharide gel from natural origin comprising aqueous composition of polysaccharides and biocompatible alcohols for the preparation of injectable formulation to treat articular degeneration and osteoarthritis
US9138405B2 (en) 2007-07-02 2015-09-22 Aptissen Sa Use of a natural polysaccharide gel for the preparation of an injectable formulation for treatment of articular degeneration
CN104825482A (en) * 2007-07-02 2015-08-12 爱体神有限公司 Use of a natural polysaccharide gel for production of an injectable formulation for treating joint degeneration
WO2009024670A3 (en) * 2007-07-02 2009-04-23 Anteis Sa Hyaluronic acid injectable gel for treating joint degeneration
US9265761B2 (en) 2007-11-16 2016-02-23 Allergan, Inc. Compositions and methods for treating purpura
US8853184B2 (en) 2007-11-30 2014-10-07 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US9238013B2 (en) 2008-08-04 2016-01-19 Allergan Industrie, Sas Hyaluronic acid-based gels including lidocaine
US9089519B2 (en) 2008-08-04 2015-07-28 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US10328180B2 (en) 2008-08-04 2019-06-25 Allergan Industrie, S.A.S. Hyaluronic acid-based gels including lidocaine
US11173232B2 (en) 2008-08-04 2021-11-16 Allergan Industrie, Sas Hyaluronic acid-based gels including lidocaine
US10391202B2 (en) 2008-08-04 2019-08-27 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US9089518B2 (en) 2008-08-04 2015-07-28 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US9089517B2 (en) 2008-08-04 2015-07-28 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US9358322B2 (en) 2008-08-04 2016-06-07 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US11020512B2 (en) 2008-08-04 2021-06-01 Allergan Industrie, Sas Hyaluronic acid-based gels including lidocaine
US10485896B2 (en) 2008-08-04 2019-11-26 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US9861570B2 (en) 2008-09-02 2018-01-09 Allergan Holdings France S.A.S. Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US9228027B2 (en) 2008-09-02 2016-01-05 Allergan Holdings France S.A.S. Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US11154484B2 (en) 2008-09-02 2021-10-26 Allergan Holdings France S.A.S. Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
EP2676658B1 (en) 2008-11-07 2015-09-16 Anteis SA Heat-sterilised injectable composition of hyaluronic acid, polyol(s) and lidocaine
EP2349203B2 (en) † 2008-11-07 2020-02-26 Anteis S.A. Heat sterilised injectable composition of hyaluronic acid or one of the salts thereof, polyols and lidocaine
FR2938187A1 (en) * 2008-11-07 2010-05-14 Anteis Sa INJECTABLE COMPOSITION BASED ON HYALURONIC ACID OR ONE OF ITS HEAT-STERILIZED SALTS, POLYOLS AND LIDOCAINE
US9040575B2 (en) 2009-12-21 2015-05-26 Professional Dietetics, S.R.L. Combination for the treatment of osteoarthritis
ITMI20092256A1 (en) * 2009-12-21 2011-06-22 Solartium Entpr Ltd USE OF A COMBINATION FOR THE TREATMENT OF OSTEOARTROSI
CN102665708A (en) * 2009-12-21 2012-09-12 专业营养有限公司 A combination for the treatment of osteoarthritis
WO2011076596A1 (en) * 2009-12-21 2011-06-30 Professional Dietetics S.R.L. A combination for the treatment of osteoarthritis
CN102665708B (en) * 2009-12-21 2014-11-05 专业营养有限公司 A combination for the treatment of osteoarthritis
US20130310437A1 (en) * 2009-12-21 2013-11-21 Professional Dietetics S.R.L. Combination for the treatment of osteoarthritis
US9855367B2 (en) 2010-01-13 2018-01-02 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use
US10220113B2 (en) 2010-01-13 2019-03-05 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use
US9333160B2 (en) 2010-01-13 2016-05-10 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use
US8946192B2 (en) 2010-01-13 2015-02-03 Allergan, Inc. Heat stable hyaluronic acid compositions for dermatological use
US10806821B2 (en) 2010-01-13 2020-10-20 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US9655991B2 (en) 2010-01-13 2017-05-23 Allergan Industrie, S.A.S. Stable hydrogel compositions including additives
US10449268B2 (en) 2010-01-13 2019-10-22 Allergan Industrie, S.A.S. Stable hydrogel compositions including additives
AU2010348090B2 (en) * 2010-03-12 2015-09-03 Allergan Industrie Sas A fluid composition comprising a hyaluronan polymer and mannitol for improving skin condition
CN102905677A (en) * 2010-03-12 2013-01-30 阿勒根工业有限公司 A fluid composition comprising a hyaluronan polymer and mannitol for improving skin condition
JP2013522283A (en) * 2010-03-12 2013-06-13 アラーガン・アンデュストリー・ソシエテ・パール・アクシオン・サンプリフィエ Fluid composition for improving skin condition
US8921338B2 (en) 2010-03-12 2014-12-30 Allergan Industrie, Sas Fluid compositions for improving skin conditions
US9125840B2 (en) 2010-03-12 2015-09-08 Allergan Industrie Sas Methods for improving skin conditions
WO2011110894A2 (en) 2010-03-12 2011-09-15 Allergan Industrie Sas Fluid composition for improving skin conditions
US9585821B2 (en) 2010-03-12 2017-03-07 Allergan Industrie Sas Methods for making compositions for improving skin conditions
WO2011110894A3 (en) * 2010-03-12 2011-11-24 Allergan Industrie Sas A fluid composition comprising a hyaluronan polymer and mannitol for improving skin condition
KR101764451B1 (en) * 2010-03-12 2017-08-02 알러간 인더스트리 에스에이에스 A Fluid Composition Comprising A Hyaluronan Polymer and Mannitol For Improving Skin Condition
JP2015164948A (en) * 2010-03-12 2015-09-17 アラーガン・アンデュストリー・ソシエテ・パール・アクシオン・サンプリフィエＡｌｌｅｒｇａｎ Ｉｎｄｕｓｔｒｉｅ Ｓａｓ Fluid compositions for improving skin conditions
US10905797B2 (en) 2010-03-22 2021-02-02 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US8691279B2 (en) 2010-03-22 2014-04-08 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US9012517B2 (en) 2010-03-22 2015-04-21 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US9480775B2 (en) 2010-03-22 2016-11-01 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
CN103282032A (en) * 2010-12-06 2013-09-04 詹弗兰科·德保利安布罗西 Carnosine-hyaluronic acid mixtures and their use
WO2012076961A3 (en) * 2010-12-06 2012-11-01 Gianfranco De Paoli Ambrosi Carnosine - hyaluronic acid mixtures and their use
US9475887B2 (en) 2010-12-06 2016-10-25 Gianfranco De Paoli Ambrosi Carnosine hyaluronic acid mixtures and their use
ITBS20100197A1 (en) * 2010-12-06 2012-06-07 Paoli Ambrosi Gianfranco De NEW COMPOUND OF CARNOSINE
RU2602297C2 (en) * 2010-12-06 2016-11-20 ПАОЛИ АМБРОЗИ Джанфранко ДЕ Carnosine-hyaluronic acid mixtures and their use
WO2012143876A1 (en) * 2011-04-19 2012-10-26 Anteis S.A. A sterile and injectable aqueous formulation for administration in the intra-articular space of an intra-articular joint
US11000626B2 (en) 2011-06-03 2021-05-11 Allergan Industrie, Sas Dermal filler compositions including antioxidants
US9149422B2 (en) 2011-06-03 2015-10-06 Allergan, Inc. Dermal filler compositions including antioxidants
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9962464B2 (en) 2011-06-03 2018-05-08 Allergan, Inc. Dermal filler compositions including antioxidants
US11083684B2 (en) 2011-06-03 2021-08-10 Allergan Industrie, Sas Dermal filler compositions
US9737633B2 (en) 2011-06-03 2017-08-22 Allergan, Inc. Dermal filler compositions including antioxidants
US10624988B2 (en) 2011-06-03 2020-04-21 Allergan Industrie, Sas Dermal filler compositions including antioxidants
US10994049B2 (en) 2011-06-03 2021-05-04 Allergan Industrie, Sas Dermal filler compositions for fine line treatment
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US9821086B2 (en) 2011-09-06 2017-11-21 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9795711B2 (en) 2011-09-06 2017-10-24 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US10434214B2 (en) 2011-09-06 2019-10-08 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US11833269B2 (en) 2011-09-06 2023-12-05 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US11844878B2 (en) 2011-09-06 2023-12-19 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
WO2013076160A1 (en) * 2011-11-21 2013-05-30 Université Libre de Bruxelles Sustained release formulations useful in the treatment of diseases
WO2013076162A1 (en) * 2011-11-21 2013-05-30 Université Libre de Bruxelles Formulations useful in the treatment of osteoarticular diseases
WO2015006460A1 (en) 2013-07-10 2015-01-15 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
US10722444B2 (en) 2014-09-30 2020-07-28 Allergan Industrie, Sas Stable hydrogel compositions including additives
US11260015B2 (en) 2015-02-09 2022-03-01 Allergan Industrie, Sas Compositions and methods for improving skin appearance
US10004824B2 (en) 2015-05-11 2018-06-26 Laboratoires Vivacy Compositions comprising at least one polyol and at least one anesthetic
CN114317497A (en) * 2021-12-14 2022-04-12 华熙生物科技股份有限公司 Hyaluronidase liquid preparation for detection and application thereof

Similar Documents

Publication Publication Date Title
WO2006067608A1 (en) Aqueous formulations based on sodium hyaluronate for parenteral use
US20210128604A1 (en) Stabilized Glycosaminoglycan Preparations and Related Methods
US8263118B2 (en) Bioresorbable fillers constituted by phospholipid liposomes and hyaluronic acid and/or the derivatives thereof
US20050123593A1 (en) Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
EP1423081A2 (en) Composition comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints
US11160766B2 (en) Peritoneal therapeutic fluid
US20140094430A1 (en) Hyaluronic acid compositions stabilised against the degrading effect of heat or enzymes
CA2424656A1 (en) Composition and method for stable injectable liquids
JP4990446B2 (en) Injection for treatment of arthropathy
ES2322985T3 (en) FORMULATIONS THAT INCLUDE TRAPPED ACTIVE INGREDIENTS AND THEIR USES.
US20080145415A1 (en) Bioresorbable Fillers Constituted by Phospholipid Liposomes and Hyaluronic Acid and/or the Derivatives Thereof
JP3050898B2 (en) Aqueous pharmaceutical preparation
US9974803B2 (en) Combination of glycosaminoglycans and cyclodextrins
JP6156762B2 (en) Thickening and viscosity reduction inhibitor for hyaluronic acid-containing aqueous preparations
JPH11302197A (en) Hyaluronic acid-stabilizing composition
WO1991008767A1 (en) STABILIZATION OF GLYCOSYLIZED t-PA
AU620821B2 (en) Hyaluronic acid lubricating compounds
CA2507870A1 (en) Method of modulating release of saccharides and uses thereof
JPH11279205A (en) Suppression of decomposition of hyaluronic acid preparations
WO2024080954A1 (en) Intra-articular gel for tissue and cartilage regeneration
CN116650425A (en) Use of sugar ester compounds or salts thereof in cryoprotection and freeze-drying protection
JPH1143446A (en) Viscosity-increasing agent for aqueous preparation
AU2002312564A1 (en) Composition comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints
AU2002312563A1 (en) Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05817738

Country of ref document: EP

Kind code of ref document: A1

WWW Wipo information: withdrawn in national office

Ref document number: 5817738

Country of ref document: EP